Is left ventricular hypertrophy a low-level inflammatory state? A population-based cohort study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 8, 2012, Pages 668-676

  Bo, S ^a   Mandrile, C ^a   Milanesio, N ^a   Pagani, A ^a   Gentile, L ^b   Gambino, R ^a   Villois, P ^a   Ghinamo, L ^a   Canil, S ^a   Durazzo, M ^a   Cassader, M ^a   Cavallo Perin, P ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b Hospital of Asti   (Italy)

Author keywords

C reactive protein; Left ventricular hypertrophy; Metabolic syndrome; Waist circumference

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN;

ARTICLE; BLOOD; CHI SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; IMMUNOLOGY; INFLAMMATION; ITALY; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TIME; UPREGULATION;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; INFLAMMATION MEDIATORS; ITALY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84864048646     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.11.004     Document Type: Article

References (37)

1. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990, 322:1561-1566.
2. Verdecchia P., Porcellati C., Reboldi G., Gattobigio R., Borgioni C., Pearson T.A., et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001, 104:2039-2044.
3. Schwartzkopff B., Motz W., Frenzel H., Vogt M., Knauer S., Strauer B.E. Structural and functional alterations of the intramyocardial coronary arterioles in patients with arterial hypertension. Circulation 1993, 88:993-1003.
4. Nadar S.K., Blann A.D., Kamath S., Beevers D.G., Lip G.Y. Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the anglo-scandinavian cardiac outcomes trial (ASCOT). J Am Coll Cardiol 2004, 44:415-422.
5. Lip G.Y., Blann A.D., Jones A.F., Lip P.L., Beevers D.G. Relation of endothelium, thrombogenesis, and hemorheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997, 80:1566-1571.
6. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999, 340:115-126.
7. Palmieri V., Celentano A., Roman M.J., de Simone G., Lewis M.R., Best L., et al. Fibrinogen and preclinical echocardiographic target organ damage. The strong heart study. Hypertension 2001, 38:1068-1074.
8. Salles G.F., Fiszman R., Cardoso C.R.L., Muxfeldt E.S. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007, 50:723-728.
9. Takei Y., Di Tullio M.R., Homma S., Boden-Albala B., Rundek T., Sacco R.L., et al. Soluble tumor necrosis factor receptor 1 level is associated with left ventricular hypertrophy: the northern Manhattan study. Am J Hypertens 2009, 22:763-769.
10. Park C.W., Shin Y.S., Kim C.M., Lee S.Y., Yu S.E., Kim S.Y., et al. Increased C-reactive protein following hemodialysis predicts cardiac hypertrophy in chronic hemodialysis patients. Am J Kidney Dis 2002, 40:1230-1239.
11. Palmieri V., Tracy R.P., Roman M.J., Liu J.E., Best L.G., Bella J.N., et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes. Diabetes Care 2003, 26:2764-2769.
12. Mehta S.K., Rame E., Khera A., Murphy S.A., Canham R.M., Peshock R.M., et al. Left ventricular hypertrophy, subclinical atherosclerosis, and inflammation. Hypertension 2007, 49:1385-1391.
13. Velagaleti R.S., Gona P., Levy D., Aragam J., Larson M.G., Tofler G.H., et al. Relation of biomarkers representing distinct biological pathways to left ventricular geometry. Circulation 2008, 118:2252-2258.
14. Iwashima Y., Horio T., Kamide K., Rakugi H., Ogihara T., Kawano Y. C-reactive protein, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertens Res 2007, 30:1177-1185.
15. Kuwahara F., Kai H., Tokuda K., Takeya M., Takeshita A., Egashira K., et al. Hypertensive myocardial fibrosis and diastolic dysfunction. Another model of inflammation?. Hypertension 2004, 43:739-745.
16. Tsioufis C., Stougiannos P., Kakkavas A., Toutouza M., Mariolis A., Vlasseros I., et al. Relation of left ventricular concentric remodeling to levels of C-reactive protein and serum amyloid A in patients with essential hypertension. Am J Cardiol 2005, 96:252-256.
17. Kapadia S.R., Yakoob K., Nader S., Thomas J.D., Mann D.L., Griffin B.P. Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. J Am Coll Cardiol 2000, 36:208-212.
18. Kannel W.B., Gordon T., Castelli W.P., Margolis J.R. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham study. Ann Intern Med 1970, 72:813-822.
19. Prineas R.J., Rautaharju P.M. Independent risk for cardiovascular disease predicted by modified continuous score electrocardiographic criteria for 6-year incidence and regression of left ventricular hypertrophy among clinically disease free men: 16-year follow-up for the multiple risk factor intervention trial. J Electrocardiol 2001, 34:91-101.
20. Da Costa W., Perez Riera A.R., De Assis Costa F., Nogueira Bombig M.T., de Paola A.A.V., Camargo Carvalho A.C., et al. Correlation of electrocardiographic left ventricular hypertrophy criteria with left ventricular mass by echocardiogram in obese hypertensive patients. J Electrocardiol 2008, 41:724-729.
21. Okin P.M., Roman M.J., Devereux R.B., Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol 1995, 25:417-423.
22. Schillaci G., Verdecchia P., Borgioni C., Ciucci A., Guerrieri M., Zampi I., et al. Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol 1994, 74:714-719.
23. Verdecchia P., Schillaci G., Borgioni C., Ciucci A., Gattobigio R., Zampi I., et al. Prognostic value of a new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998, 31:383-390.
24. Okin P.M., Devereux R.B., Jern S., Kjeldsen S.E., Julius S., Dahlöf B. Effects of obesity on electrocardiographic left ventricular hypertrophy in hypertensive patients: the losartan intervention for endpoint (LIFE) reduction in hypertension study. Hypertension 2000, 35:13-18.
25. Okin P.M., Roman M.J., Devereux R.B., Kligfield P. Electrocardiographic identification of left ventricular hypertrophy: test performance in relation to definition of hypertrophy and presence of obesity. J Am Coll Cardiol 1996, 27:124-131.
26. Bo S., Gentile L., Ciccone G., Baldi C., Benini L., Dusio F., et al. The metabolic syndrome and high C-reactive protein: prevalence and difference by sex in a southern-European population-based cohort. Diabetes Metab Res Rev 2005, 21:515-524.
27. Taylor H.L., Jacobs D.R., Schucker B., Knudsen J., Leon A.S., Debacker G. Questionnaire for the assessment of leisure time physical activities. J Chronic Dis 1978, 31:741-755.
28. Bo S., Durazzo M., Guidi S., Carello M., Sacerdote C., Silli B., et al. Dietary magnesium and fiber intake, inflammatory and metabolic parameters in middle-aged subjects from a population-based cohort. Am J Clin Nutr 2006, 84:1062-1069.
29. Bo S., Gambino R., Pagani A., Guidi S., Gentile L., Cassader M., et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes 2005, 29:1315-1320.
30. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-441.
31. Yokoyama H., Emoto M., Fujiwara S., Motoyama K., Morioka T., Komatsu M., et al. Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients. Diabetes Care 2003, 26:2426-2432.
32. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J Am Med Assoc 2001, 285:2486-2497. National Institute of Health.
33. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003, 26:S5-S20. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
34. Kapadia S.R., Oral H., Lee J., Nakano M., Taffet G.E., Mann D.L. Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium. Circ Res 1997, 81:187-195.
35. Levy D., Salmeron M., D'Agostino R.B., Belanger A.J., Kannel W.B. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90:1786-1793.
36. Sundstrom J., Lind L., Arnlov J., Zethelius B., Andren B., Lithell H.O. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation 2001, 103:2346-2351.
37. Bonora E., Targher G., Alberiche M., Bonadonna R.C., Saggiani F., Zenere M.B., et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000, 23:57-63.